Gilead’s Livdelzi wins FDA approval, can challenge Ocaliva dominance in primary biliary cholangitis… GlobalData Aug 23, 2024 The approval could present a major challenge to Ocaliva (obeticholic acid), which was until recently the sole approved drug for…
Successive drug launches will drive growth of NASH market in seven major markets: GlobalData EP News Bureau Nov 23, 2020 The NASH market will undergo a very rapid growth, at a compound annual growth rate (CAGR) of 68.8 per cent from 2019 to 2029
